Browse News

Found 61 articles

• Ultimovacs Announces New UV1 Data Showing Enhanced Efficacy Including in Hard-to-Treat Cancer Patients, Supporting Broad Utility

  10/18/2022

  Ultimovacs ASA presented clinical endpoints and biomarker results from patients in the UV1-103 phase I trial, at the 19th International Conference of the Society for Melanoma Research, being held 17-20 October in Edinburgh, UK.

• Combination Cancer Therapy Clinical Trials Report 2028

  8/23/2022

  Kuick Research Report Gives Comprehensive Clinical & Commercial Opportunity Insights More Than 600 Combination Cancer Drugs In Clinical Trials

• Peptide Cancer Vaccine Market Size, Share, Growth, Trends, Report 2022-2030

  7/6/2022

  The global Peptide Cancer Vaccine market size is estimated to be worth US$ 546.9 million in 2021 and is forecast to a readjusted size of US$ 1964.1 million by 2030 with a CAGR of 19.8% during the forecast period 2022-2030.

• Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma

  6/30/2022

  Ultimovacs ASA, a clinical stage leader in immune stimulatory vaccines for cancer, announces the completed recruitment of 154 patients in the INITIUM trial.

• Telomerase Reverse Transcriptase Market Size, Share, Global Key Findings, Industry Demand, Regional Analysis 2022 to 2030

  6/3/2022

  QY Research Medical published a comprehensive research on Telomerase Reverse Transcriptase Market, which provides a business strategies, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

• Peptide Cancer Vaccine Market: Increase in the Pool of Cancer Patients to Drive the Market

  5/5/2022

  Albany NY, United States: Vaccines are biological products which stimulate the immune system of the body to protect the body against foreign substances.

• Ultimovacs Hosting Key Opinion Leader Webinar on the Evolving Treatment Landscape of Melanoma

  3/21/2022

  Ultimovacs ASA announced that it will host a key opinion leader webinar on the unmet need and treatment landscape of melanoma on Monday, March 28, 2022 at 10:00amET/4:00amCET.

• Ultimovacs ASA: Fourth quarter 2021 result presentation

  2/17/2022

  Ultimovacs ASA, a clinical stage leader in immune stimulatory vaccines for cancer, announces its fourth quarter 2021 results .

• Peptide Cancer Vaccine Market Size, Share, Industry Growth, Trend, Business Opportunities, Challenges, Drivers and Restraint Research Report by 2027

  2/10/2022

  The industry analysis report is considered a valuable source of information about the global Peptide Cancer Vaccine industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

• 

  Clinical Catch-Up: January 31-February 4

  2/7/2022

  It was a relatively quiet week for clinical trial announcements. Here’s a look.

• Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study

  2/3/2022

  Oslo, 3 February2022: Ultimovacs ASA, a clinical stage leader in immune stimulatory vaccines for cancer, announced it has completed treatment of the second dose cohort in the Phase I TENDU trial.

• 

  Beyond COVID-19: the Potential of mRNA in Occupational Cancer

  1/13/2022

  According to the Environmental Litigation Group, P.C., approximately 37.5% of all occupational lung cancer cases are related to occupational asbestos exposure.

• First Patient Enrolled in Phase II DOVACC trial of UV1 in Advanced Ovarian Cancer

  12/15/2021

  Ultimovacs ASA, a clinical stage leader in immune stimulatory vaccines for cancer, announced that the first patient has been enrolled in the DOVACC study, a randomized Phase II clinical trial assessing the impact of the Company’s telomerase vaccine, UV1, on the standard of maintenance care in ovarian cancer.

• 

  BioSpace Movers & Shakers, Dec. 3

  12/3/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma

  12/2/2021

  Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announces that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for the company’s universal cancer vaccine UV1 for the treatment of stage IIB – IV melanoma.

• Ultimovacs ASA: Third quarter 2021 result presentation

  11/11/2021

  Oslo, 11November 2021: Ultimovacs ASA, a clinical stage leader in immune stimulatory vaccines for cancer, announces its third quarter 2021 results.

• Ultimovacs’ SITC2021 Data Shows Enduring T cell Response for UV1 Combination in Melanoma

  11/9/2021

  Ultimovacs ASA will present the data will be presented as a poster at the Society For Immunotherapy of Cancer’s 36th Annual Meeting (SITC2021) being held in Washington, DC, USA November 10-14, 2021.

• 

  Clinical Catch-Up: October 25-29

  11/1/2021

  Yet another busy week for clinical trial news. Here’s a look.

• Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC)

  10/26/2021

  Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced that the company’s universal cancer vaccine, UV1, will be investigated in a new Phase II clinical trial in combination with pembrolizumab in non-small cell lung cancer (NSCLC).

• 

  FDA Puts Ultimovac's Cancer Vaccine Support Therapy on Fast Track

  10/22/2021

  The designation is based on data from two Phase I trials, which showed the drug to be safe, demonstrating early efficacy.